These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35191521)

  • 1. ATR inhibitor AZD6738 increases the sensitivity of colorectal cancer cells to 5‑fluorouracil by inhibiting repair of DNA damage.
    Suzuki T; Hirokawa T; Maeda A; Harata S; Watanabe K; Yanagita T; Ushigome H; Nakai N; Maeda Y; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takahashi H; Takiguchi S
    Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35191521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells.
    Harata S; Suzuki T; Takahashi H; Hirokawa T; Kato A; Watanabe K; Yanagita T; Ushigome H; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takiguchi S
    Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36734271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
    Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
    Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    PLoS One; 2022; 17(4):e0266476. PubMed ID: 35413091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
    Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
    Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation.
    Bright SJ; Manandhar M; Flint DB; Kolachina R; Ben Kacem M; Martinus DK; Turner BX; Qureshi I; McFadden CH; Marinello PC; Shaitelman SF; Sawakuchi GO
    JCI Insight; 2024 Oct; 9(19):. PubMed ID: 39235982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
    Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
    Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer.
    Abdalla AN; Malki WH; Qattan A; Shahid I; Hossain MA; Ahmed M
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33440689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Bang JH; Oh KS; Seo HR; Oh DY; Bang YJ
    Cancer Res Treat; 2020 Jul; 52(3):945-956. PubMed ID: 32311864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5‑FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53‑mutated colon cancer cells.
    Akasaka T; Tsujii M; Kondo J; Hayashi Y; Ying J; Lu Y; Kato M; Yamada T; Yamamoto S; Inoue T; Tsujii Y; Maekawa A; Fujinaga T; Shiraishi E; Hiyama S; Inoue T; Shinzaki S; Watabe K; Nishida T; Iijima H; Takehara T
    Int J Oncol; 2015 Jan; 46(1):63-70. PubMed ID: 25310623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment-Resistant Cancer Cells.
    Barnieh FM; Morais GR; Loadman PM; Falconer RA; El-Khamisy SF
    Adv Sci (Weinh); 2024 Sep; 11(34):e2403831. PubMed ID: 38976561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy.
    Dunne V; Ghita M; Small DM; Coffey CBM; Weldon S; Taggart CC; Osman SO; McGarry CK; Prise KM; Hanna GG; Butterworth KT
    Radiother Oncol; 2017 Sep; 124(3):475-481. PubMed ID: 28697853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.
    Dillon MT; Barker HE; Pedersen M; Hafsi H; Bhide SA; Newbold KL; Nutting CM; McLaughlin M; Harrington KJ
    Mol Cancer Ther; 2017 Jan; 16(1):25-34. PubMed ID: 28062704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
    Min A; Im SA; Jang H; Kim S; Lee M; Kim DK; Yang Y; Kim HJ; Lee KH; Kim JW; Kim TY; Oh DY; Brown J; Lau A; O'Connor MJ; Bang YJ
    Mol Cancer Ther; 2017 Apr; 16(4):566-577. PubMed ID: 28138034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
    Yao J; Huang A; Zheng X; Liu T; Lin Z; Zhang S; Yang Q; Zhang T; Ma H
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):419-431. PubMed ID: 27838786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α‑Phellandrene enhances the apoptosis of HT‑29 cells induced by 5‑fluorouracil by modulating the mitochondria‑dependent pathway.
    Susanto AC; Hartajanie L; Wu CC
    Oncol Rep; 2024 Apr; 51(4):. PubMed ID: 38456489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
    Wang C; Wang G; Feng X; Shepherd P; Zhang J; Tang M; Chen Z; Srivastava M; McLaughlin ME; Navone NM; Hart GT; Chen J
    Oncogene; 2019 Apr; 38(14):2451-2463. PubMed ID: 30532030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.